Wells Fargo analyst Derek Archila raised the firm’s price target on Argenx (ARGX) to $756 from $741 and keeps an Overweight rating on the shares post the Q2 report. The firm believes the Vyvgart launches will continue to revenue beats in the second half of 2025 and 2026. Argenx’s commentary on Vyvgart pricing “should greatly alleviate concerns” on revenue growth, the analyst tells investors in a research note. Wells continues to like the shares at current levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx SE’s Strong Q2 Performance and Positive Outlook Reinforce Buy Rating
- Argenx SE Reports Robust Second Quarter 2025 Financial Results and Strategic Advancements
- Argenx’s Strong Financial Performance and Growth Prospects Justify Buy Rating
- Argenx reports Q2 EPS $3.74, consensus $3.05
- Argenx’s Promising Study on Efgartigimod PH20 SC: A Potential Game-Changer for Myopathy Treatment